{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:07:02Z","timestamp":1785002822658,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","atherosclerosis-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.atherosclerosis.2015.07.038","type":"journal-article","created":{"date-parts":[[2015,7,23]],"date-time":"2015-07-23T01:52:15Z","timestamp":1437616335000},"page":"295-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy"],"prefix":"10.1016","volume":"242","author":[{"given":"Jason A.","family":"Harmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C.","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Veillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Skilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Marwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5657-9811","authenticated-orcid":false,"given":"Ian T.","family":"Meredith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Celermajer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib1","series-title":"National Diabetes Data Group Diabetes Data Compliled","article-title":"Diabetes and heart disease","author":"Barrett-Connor","year":"1984"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib3","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib4","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00125-010-1854-1","article-title":"Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"54","author":"Drury","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00125-010-1951-1","article-title":"Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"54","author":"Davis","year":"2011","journal-title":"Diabetologia"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib6","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib7","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1093\/eurheartj\/ehp377","article-title":"Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"31","author":"Burgess","year":"2010","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1464-5491.2005.01688.x","article-title":"Urinary albumin levels in the normal range determine arterial wall thickness in adults with type 2 diabetes: a FIELD substudy","volume":"22","author":"Keech","year":"2005","journal-title":"Diabet. Med."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib10","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.jacc.2008.09.049","article-title":"Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus","volume":"52","author":"Hiukka","year":"2008","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib11","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1161\/01.CIR.91.5.1314","article-title":"Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in\u00a0vivo","volume":"91","author":"Joannides","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib12","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/0140-6736(92)93147-F","article-title":"Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis","volume":"340","author":"Celermajer","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib13","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/S0002-9149(02)02847-3","article-title":"Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus","volume":"90","author":"Playford","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0021-9150(02)00417-3","article-title":"Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes","volume":"168","author":"Playford","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib15","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1042\/CS20090568","article-title":"Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated type 2 diabetic patients","volume":"118","author":"Hamilton","year":"2010","journal-title":"Clin. Sci."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0021-9150(96)06018-2","article-title":"Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease","volume":"129","author":"Neunteufl","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0002-8703(99)70189-4","article-title":"Noninvasive determination of endothelium-mediated vasodilation as a screening test for coronary artery disease: pilot study to assess the predictive value in comparison with angina pectoris, exercise electrocardiography, and myocardial perfusion imaging","volume":"138","author":"Schroeder","year":"1999","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2840-4-13","article-title":"Fenofibrate intervention and event lowering in diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]","volume":"4","author":"Scott","year":"2005","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2840-3-9","article-title":"The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the fenofibrate intervention and event lowering in diabetes (FIELD) study. [ISRCTN64783481]","volume":"3","year":"2004","journal-title":"Cardiovasc Diabetol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib20","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/hrt.74.3.247","article-title":"Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility","volume":"74","author":"Sorensen","year":"1995","journal-title":"Br. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib22","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1161\/01.CIR.88.5.2149","article-title":"Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults","volume":"88","author":"Celermajer","year":"1993","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/hrt.74.3.247","article-title":"Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility","volume":"74","author":"Sorensen","year":"1995","journal-title":"Br. Heart J."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib24","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/01.CIR.94.3.258","article-title":"Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study","volume":"94","author":"Mancini","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib25","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib26","first-page":"146","article-title":"Normal ranges for brachial artery flow-mediated dilation: a non-invasive ultrasound test of arterial endothelial function","volume":"2","author":"Adams","year":"1996","journal-title":"J.\u00a0Vasc. Invest."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib27","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans affairs high-density lipoprotein intervention trial (VA-HIT)","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib28","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib29","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cardiores.2007.03.006","article-title":"Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway","volume":"75","author":"Blanco-Rivero","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the fenofibrate intervention and event lowering in diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib31","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1161\/ATVBAHA.112.300665","article-title":"Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor alpha-dependent and independent mechanisms in human endothelial cells","volume":"33","author":"Glineur","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib32","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.lfs.2008.02.002","article-title":"PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation","volume":"82","author":"Okayasu","year":"2008","journal-title":"Life Sci."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.diabres.2014.08.029","article-title":"Cigarette smoking and albuminuria are associated with impaired arterial smooth muscle function in patients with type 2 diabetes mellitus: a FIELD substudy","volume":"106","author":"Harmer","year":"2014","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib34","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/01.ATV.0000118682.58708.78","article-title":"Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells","volume":"24","author":"Goya","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.bbrc.2006.01.052","article-title":"Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC","volume":"341","author":"Murakami","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib36","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00210-005-1060-8","article-title":"Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity","volume":"371","author":"Yang","year":"2005","journal-title":"Naunyn-Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib37","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.atherosclerosis.2003.12.004","article-title":"Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration","volume":"173","author":"Dierkes","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib38","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00109-007-0257-3","article-title":"Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose","volume":"86","author":"Zanetti","year":"2008","journal-title":"J.\u00a0Mol. Med."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib39","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.vph.2006.02.006","article-title":"Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells","volume":"44","author":"Dragomir","year":"2006","journal-title":"Vasc. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib40","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diacare.25.7.1198","article-title":"Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia","volume":"25","author":"Athyros","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2796.2000.00646.x","article-title":"Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety","volume":"247","author":"Gavish","year":"2000","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib42","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.clinthera.2004.10.008","article-title":"Comparison of fluvastatin\u00a0+ fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial","volume":"26","author":"Derosa","year":"2004","journal-title":"Clin. Ther."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib43","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.amjcard.2007.09.095","article-title":"Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the diabetes and combined lipid therapy regimen study)","volume":"101","author":"May","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2015.07.038_bib44","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N.\u00a0Engl. J. Med."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015300587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915015300587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T12:32:04Z","timestamp":1566995524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915015300587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0021915015300587"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.038","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fenofibrate effects on arterial endothelial function in adults with type 2 diabetes mellitus: A FIELD substudy","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2015.07.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}